Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were two new molecular entities.
December 17, 1:42 PM
December 17, 1:03 PM
Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor.
OPKO Biologies Granted U.S. Patent #11,197,915 ‘Long-acting polypeptides and methods of producing and administering same’
December 14, 9:17 AM
View Patent Here
December 8, 9:02 AM
OPKO Health, Inc. (NASDAQ:OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved OPKO’s 4Kscore Test. This test is approved for use in men age 45 and older who have not had a
OPKO Health’s BioReference Laboratories Announces Readiness For COVID-19 Testing If Omicron COVID-19 Variant Emerges In U.S
November 29, 11:25 AM
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced COVID-19 testing preparedness for the Omicron Variant. BioReference's PCR diagnostic tests for SARS-CoV-2 COVID-19 are based on
October 28, 4:53 PM
October 28, 4:24 PM
OPKO Health (NASDAQ:OPK) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.01) by 500 percent. This is unchanged from the same period last year. The company reported